Streetbeat News

Stock Prices

GANX

Gain Therapeutics (NASDAQ:GANX) reported a Q2 2024 GAAP EPS of $(0.42), missing the analyst consensus estimate of $(0.20) by 110%. This represents a 32.26% improvement over the $(0.62) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:49 am

CLPT

ClearPoint Neuro shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:49 am

PGEN

Precigen shares are trading lower following the announcement of a $30 million public offering, pricing 35,294,118 shares at $0.85 each.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:48 am

ARHS

Arhaus (NASDAQ:ARHS) reported Q2 2024 GAAP EPS of $0.16, beating the estimate of $0.12 by 33.33%. However, sales of $309.801M missed the $314.309M estimate by 1.43%, and decreased by 0.99% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:48 am

NNVC

NanoViricides has provided an update on its clinical program and strategy in a letter to shareholders. The company highlighted NV-387, an antiviral drug, which it claims could be as revolutionary as antibiotics.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:46 am

CABA

Cabaletta Bio shares are trading lower following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:46 am

HHH

Howard Hughes Corporation (HHH) has acknowledged Pershing Square Capital Management's regulatory filing and has formed a special committee to review any proposals. Pershing Square, HHH's largest stockholder with 37.5% ownership, is evaluating various potential alternatives, including a possible transaction.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:43 am

AGS

BYD

GENI

WYNN

Boyd Gaming (NYSE:BYD) reported Q2 earnings with an EPS of $1.58, beating estimates by 6.0%. Revenue increased by $50.56 million year-over-year. Competitors Wynn Resorts, Genius Sports, and PlayAGS had mixed earnings results.

Portfolio Pulse from Benzinga Insights

August 08, 2024 | 11:43 am

NVAX

Novavax (NASDAQ:NVAX) reported Q2 2024 earnings per share (EPS) of $0.99, missing the analyst consensus estimate of $1.64 by 39.63%. The company also reported quarterly sales of $415.484 million, which missed the analyst consensus estimate of $458.575 million by 9.40%. This represents a 2.11% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:42 am

PRTH

Priority Technology Holdings, Inc. (PRTH) has revised its FY24 revenue forecast from the previous range of $875M - $890M to a new range of $875M - $883M. The estimated revenue is $874.686M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:41 am